Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial
The Journal of Clinical Endocrinology & Metabolism · 16.06.2023 · 108 (7) · 1696-1708
DOI: 10.1210/clinem/dgad015 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 12.01.2023. Verfasst von Elizabeth Roof und 36 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University, Nashville, TN 37240, USA. Hauptthemen laut MEDLINE: Prader-Willi Syndrome, COVID-19. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Context
Prader-Willi syndrome (PWS) is a rare genetic disorder characterized by endocrine and neuropsychiatric problems including hyperphagia, anxiousness, and distress. Intranasal carbetocin, an oxytocin analog, was investigated as a selective oxytocin replacement therapy.
Objective
To evaluate safety and efficacy of intranasal carbetocin in PWS.
Design
Randomized, double-blind, placebo-controlled phase 3 trial with long-term follow-up.
Setting
Twenty-four ambulatory clinics at academic medical centers.
Participants
A total of 130 participants with PWS aged 7 to 18 years.
Interventions
Participants were randomized to 9.6 mg/dose carbetocin, 3.2 mg/dose carbetocin, or placebo 3 times daily during an 8-week placebo-controlled period (PCP). During a subsequent 56-week long-term follow-up period, placebo participants were randomly assigned to 9.6 mg or 3.2 mg carbetocin, with carbetocin participants continuing at their previous dose. Main outcome measures Primary endpoints assessed change in hyperphagia (Hyperphagia Questionnaire for Clinical Trials [HQ-CT]) and obsessive-compulsive symptoms (Children's Yale-Brown Obsessive-Compulsive Scale [CY-BOCS]) during the PCP for 9.6 mg vs placebo, and the first secondary endpoints assessed these same outcomes for 3.2 mg vs placebo. Additional secondary endpoints included assessments of anxiousness and distress behaviors (PWS Anxiousness and Distress Behaviors Questionnaire [PADQ]) and clinical global impression of change (CGI-C).
Results
Because of onset of the COVID-19 pandemic, enrollment was stopped prematurely. The primary endpoints showed numeric improvements in both HQ-CT and CY-BOCS which were not statistically significant; however, the 3.2-mg arm showed nominally significant improvements in HQ-CT, PADQ, and CGI-C scores vs placebo. Improvements were sustained in the long-term follow-up period. The most common adverse event during the PCP was mild to moderate flushing.
Conclusions
Carbetocin was well tolerated, and the 3.2-mg dose was associated with clinically meaningful improvements in hyperphagia and anxiousness and distress behaviors in participants with PWS. Clinical Trials Registration Number NCT03649477
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vanderbilt University, Nashville, TN 37240, USA.
- Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montréal, Québec H3T 1C5, Canada.
- Department of Pediatrics, Section of Genetics and Metabolism, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO 80309, USA.
- Department of Psychiatry, The University of Tennessee Health Science Center College of Medicine, Memphis, TN 37996, USA.
- Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL 32611, USA.
- Division of Endocrinology, The Hospital for Sick Children, Toronto M5G 1X8, Canada.
ORCID-Profile: Cheri L Deal, Shawn E McCandless, Ronald L Cowan, Elizabeth R Roeder, Shana E McCormack, Tamanna R Roshan Lal, Hussein D Abdul-Latif, Andrea M Haqq, Kathryn S Obrynba, Laura C Torchen, Alaina P Vidmar, David H Viskochil, Jean-Pierre Chanoine, Melinda J Pierce, Laurel L Williams, Lynne M Bird, Merlin G Butler, Diane E Jensen, Laura J Chalmers, Cary Fu, Nathalie Alos, Brent A Blumenstein, Davis C Ryman
Zitieren
APA
Roof, E., Deal, C. L., McCandless, S. E., Cowan, R. L., Miller, J. L., Hamilton, J. K., Roeder, E. R., McCormack, S. E., Roshan Lal, T. R., Abdul-Latif, H. D., Haqq, A. M., Obrynba, K. S., Torchen, L. C., Vidmar, A. P., Viskochil, D. H., Chanoine, J. P., Lam, C. K. L., Pierce, M. J., Williams, L. L., …, & Ryman, D. C. (2023). Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial. The Journal of Clinical Endocrinology & Metabolism, 108(7), 1696-1708. https://doi.org/10.1210/clinem/dgad015
Vancouver
Roof E, Deal CL, McCandless SE, Cowan RL, Miller JL, Hamilton JK, et al. Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial. The Journal of Clinical Endocrinology & Metabolism. 2023;108(7):1696-1708. doi:10.1210/clinem/dgad015
BibTeX
@article{Roof2023,
author = {Roof, Elizabeth and Deal, Cheri L and McCandless, Shawn E and Cowan, Ronald L and Miller, Jennifer L and Hamilton, Jill K and Roeder, Elizabeth R and McCormack, Shana E and Roshan Lal, Tamanna R and Abdul-Latif, Hussein D and Haqq, Andrea M and Obrynba, Kathryn S and Torchen, Laura C and Vidmar, Alaina P and Viskochil, David H and Chanoine, Jean-Pierre and Lam, Carol K L and Pierce, Melinda J and Williams, Laurel L and Bird, Lynne M and Butler, Merlin G and Jensen, Diane E and Myers, Susan E and Oatman, Oliver J and Baskaran, Charumathi and Chalmers, Laura J and Fu, Cary and Alos, Nathalie and McLean, Scott D and Shah, Ajay and Whitman, Barbara Y and Blumenstein, Brent A and Leonard, Sarah F and Ernest, Jessica P and Cormier, Joseph W and Cotter, Sara P and Ryman, Davis C},
title = {Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {7},
pages = {1696--1708},
doi = {10.1210/clinem/dgad015}
}
EUVIMED